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ABSTRACT 
Background: 
The use of Extracorporeal membrane oxygenation (ECMO) has steadily increased in the last 
decades and has evolved in several ways. From originally being a means to support the 
neonatal patient with respiratory or circulatory failure for days to weeks, ECMO is now 
mainly used in paediatric and adult patients. 
Survival after ECMO varies depending on the underlying condition, and survival to discharge 
and 6-12 months has been readily reported in the literature. Likewise, quality-of-life and 
health status are well-investigated in the 3-24-month period after discharge. However, there is 
a paucity of data concerning long-term outcomes several years after ECMO treatment.  
Aim: 
To identify long-term survival and causes of death in ECMO treated patients (study I and II), 
and to investigate the long-term health and mental status after treatment, including cognitive 
functions and brain radiographic findings (study III), pulmonary function, pulmonary 
morphology, mood disorders and quality of life (study IV). 
Overview of methods: 
Using the Swedish national causes of death registry, study I and II attained survival status and 
causes of death in all commonly treated patient groups at the ECMO Centre of the Karolinska 
University Hospital. Survival was depicted using the Kaplan-Meier technique. For study III 
and IV, a retrospective cohort was created by contacting consecutive long-term adult 
survivors, starting with the first adult survivor treated at the centre. Thirty-eight patients 
treated with ECMO for respiratory failure were investigated. This included magnetic 
resonance imaging of the brain and extensive neurocognitive tests (study III), followed by 
computed tomography of the lungs, spirometry, a six-minute walk test and self-reported 
forms of quality of life and mood symptoms (study IV, including Short form 36, St George’s 
respiratory questionnaire, Hospital anxiety and depression scale and Trauma screening 
questionnaire). 
Summary of research results: 
Survival status in 255 adults was investigated in median 4.4 years after treatment (study I). 
The mortality was high in the first three months after treatment (17% of the ECMO survivors 
died in the first 90 days). This time point served as a cut-off to define late survival. In patients 
who were alive at 90 days, 87% were alive five years later. Long-term survival differed 
between groups and was highest in patients treated for a known or suspected infectious 
disease. In study II, 400 children were investigated in median 7.2 years after treatment. 
Similar to the results in adults, there was high 90-day mortality, and 93% of neonates and 
89% of paediatric patients were alive 10 years later in the group who survived to this time 
 
 
point. Patients who died generally had severe comorbidities or an underlying disease which 
caused deterioration later in life. 
Brain lesions were seen in 37% of the long-term survivors (14/38, study III). In the group 
treated with venoarterial ECMO, 64% had signs of brain lesions. General intelligence 
depicted as the full-scale intelligence quotient (normal mean 100, SD 15) was 97 in median 
(IQR 86-104). In patients with brain lesions, the median full-scale intelligence quotient was 
88, compared to 102 in patients with normal brain imaging (p=0.28). Memory functions and 
executive functions, also reported as indices with a normal mean of 100 and a SD of 15, were 
significantly reduced in patients with brain lesions (p=0.03 and 0.02, respectively). Patients 
with hypoxaemia during ECMO treatment, defined as <93% pulse oximetry haemoglobin 
saturation in median during ECMO treatment (or the first 10 days if treated for a long time) 
had similar intelligence as patients with normoxaemia.  
Quality of life was reduced in the present cohort, but the results were similar to previously 
published data on patients with acute respiratory distress syndrome not treated with ECMO. 
A reduction in diffusion capacity was seen in 47% of the patients, and lung function varied 
greatly between patients. Lung parenchymal damage was common, in mean 7% of the 
parenchyma was damaged (range 0-44%). In 50% of the patients, this damage was 
predominantly localised anteriorly, possibly indicating ventilator-induced lung injury. 
Parenchymal damage correlated with time on ECMO and time with mechanical ventilation, 
and with reductions in quality of life and diffusion capacity.  
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LIST OF ABBREVIATIONS 
6MWD Six-minute walk test (distance) 
ARDS Acute respiratory distress syndrome 
CD Cognitive dysfunction 
CDH Congenital diaphragmatic hernia 
CMV Conventional mechanical ventilation (as opposed to ECMO 
treatment) 
CPB Cardiopulmonary bypass 
CPR Cardiopulmonary resuscitation 
CVL Cerebrovascular lesion 
DLCO Diffusing capacity of the lungs for carbon monoxide 
ECK ECMO Centre Karolinska 
ECMO Extracorporeal membrane oxygenation 
ECPR Extracorporeal cardiopulmonary resuscitation 
ELSO Extracorporeal life support organization 
FiO2 Fraction of inspired oxygen 
FSIQ Full-scale intelligence quotient 
HADS Hospital anxiety and depression scale 
HFOV High-frequency oscillatory ventilation 
HRCT High-resolution computed tomography 
ICU Intensive care unit 
IQR Interquartile range 
MAS Meconium aspiration syndrome 
MRI Magnetic resonance imaging 
OI Oxygenation index 
PaO2 Arterial partial pressure of oxygen 
PEEP Positive end-expiratory pressure 
PF ratio PaO2/FiO2 
PTSD Post-traumatic stress disorder 
RCT Randomised controlled trial 
 
 
 
SaO2 Haemoglobin oxygen saturation in arterial blood (measured 
by blood analysis) 
SD Standard deviation 
SF-36 Short form 36 (36-item health survey) 
SGRQ St George's Respiratory Questionnaire 
SpO2 Haemoglobin oxygen saturation in arterial blood (measured 
by pulse oximetry) 
SvO2 Haemoglobin oxygen saturation in venous blood (measured 
by blood analysis) 
TSQ Trauma screening questionnaire 
VA ECMO Venoarterial ECMO 
VILI Ventilator-induced lung injury 
VV ECMO Venovenous ECMO 
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1 INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) supports the heart and lungs in cases of 
severe circulatory or respiratory failure, refractory to conventional treatment methods. Since 
its introduction in the 1970s, more than 100,000 patients have been reported to the 
international extracorporeal life support organization (ELSO) registry (1). The use of ECMO 
in adults is increasing, aided by new indications such as ECMO for cardiopulmonary 
resuscitation (ECPR; [2]) and favourable outcomes in randomised controlled trials (3-4) and 
the pandemic H1N1 influenza (5). ECMO is an invasive and costly procedure, associated 
with potentially severe side effects. It is therefore natural to ask what the long-term effects 
are. In other words: how is life after ECMO? What is the long-term survival and 
survivorship? These questions were addressed in my doctoral thesis. 
2 BACKGROUND 
2.1 WHAT IS ECMO? 
Extracorporeal membrane oxygenation is a modified heart-lung machine which oxygenates 
the blood through a membrane lung outside of the body (extracorporeally). In this way, 
ECMO may help or fully replace the major functions of the lungs (oxygenation, 
decarboxylation) and heart (circulate the blood and maintain adequate organ perfusion) when 
these organs are failing, for short or extended periods of time. ECMO is used in specialised 
intensive care units (ICUs) and is not a treatment in itself but provides life-support while 
other treatments such as antibiotics or surgery, or the immune system itself, heals the 
underlying condition. ECMO is an invasive and resource intense treatment option and is 
normally only instituted when the patient’s prognosis is considered poor despite maximal 
intensive care treatment. Terminology wise, ECMO and ECLS (extracorporeal life support) 
are used synonymously, and there are several modified techniques available, such as 
extracorporeal carbon dioxide removal (ECCO2R), which uses low-flow ECMO for 
decarboxylation. (6) 
2.1.1 The ECMO circuit 
The ECMO circuit is illustrated in Figure 1. In short, a suction cannula is inserted in one of 
the great veins, usually the femoral or internal jugular vein. The blood is circulated with a 
pump in large tubing through the oxygenator, warmed, and then returned to the body. For 
respiratory failure without heart failure, ECMO is usually used in a venovenous (VV) 
configuration. In VV ECMO, the return cannula is inserted into one of the great veins, 
leaving oxygenated and decarboxylated blood for the patient’s own heart to circulate through 
the native lungs and then further out to the body through the aorta. When heart failure is 
present or imminent, venoarterial (VA) ECMO is used, i.e. the return cannula is inserted in 
one of the great arteries, usually the femoral artery (called peripheral cannulation as opposed 
to central cannulation in the aorta, which demands a thoracotomy).  
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Figure 1. Schematic illustration of an ECMO circuit, showing the suction cannula with deoxygenated 
venous blood (blue), the ECMO system and the return cannula with oxygenated blood (red) which can 
be inserted into a major vein (venovenous or “VV ECMO”) or artery (venoarterial or “VA ECMO”). 
Image by Jürgen Schaub downloaded from Wikipedia Commons, modified by the author. 
https://commons.wikimedia.org/wiki/File:Ecmo_schema-1-.jpg 
 
2.1.2 Mechanical ventilation 
During ECMO, the patients receive mechanical ventilation, sedation, analgesia and other 
intensive care as needed. Mechanical ventilation pressures, often needed in potentially 
harmful levels before ECMO is started, are reduced significantly after ECMO cannulation to 
allow the lungs to rest and to minimise ventilator-induced lung injury (7-8).  
2.1.3 Altered physiology and side effects 
Anticoagulation (usually heparin) is used to reduce the risk of blood clots due to the 
introduction of foreign surfaces and altered blood flow (9). The body’s normal physiology is 
also altered, namely with great local changes in blood flow where cannulas are inserted, and a 
continuous as opposed to pulsatile flow. Cannula positioning is of vital importance to avoid 
recirculation of blood between the return and drainage cannulas (which may cause 
hypoxaemia in VV ECMO) and to enable a high flow through the circuit. In peripheral VA 
ECMO with the return cannula in the femoral artery, the blood flow in the aorta is retrograde 
(oxygenated blood from the ECMO system), which may meet and mix with an anterograde 
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blood flow if the patient has an intrinsic cardiac output (usually with poor oxygenation 
through failing lungs). In this case, turbulence is created, and some parts of the body 
(typically the right subclavian and the carotid arteries) may receive blood with lower oxygen 
saturations (termed “harlequin syndrome” or differential hypoxia). If a gas bubble or blood 
clot accidentally leaves the ECMO machine, the lungs usually filter these with no or little 
harm in VV ECMO, but with potentially detrimental effects in VA ECMO since the lungs are 
bypassed. (10) 
Major side effects include blood thrombus formation and air embolism, but also bleeding due 
to the anticoagulation used and the invasiveness of the technique (11). Bleeding and ischemic 
lesions within the central nervous system are among the most feared complications since they 
are hard to treat and may cause life-long disabilities if not lethal (12). Due to the introduction 
of foreign surfaces through the skin, infections are common. As with all long-term treatment 
in the ICU, the effects of systemic inflammation, catabolism and drugs may cause short and 
long-term problems, including muscle weakness, nerve damage, delirium, cognitive 
dysfunction, post-traumatic stress disorder (PTSD) and anxiety (13-14).  
2.1.4 Economic considerations 
A large international study reported mean ECMO treatment health care costs of 
approximately £74,000 in 2006 (~50,300 € with the average exchange rate of the time) 
compared to £33,400 (~22,700 €) for conventionally treated patients (3).  
2.2 HISTORY OF ECMO 
In the 1930s, a young surgeon named John Heysham Gibbon Jr was asked to watch over a 
patient with massive pulmonary embolism. At the time, a surgical embolectomy was the only 
definite treatment option but constituted a high risk for the patient, and doctor Gibbon was 
assigned to follow the vital signs of the patient and to call in a senior colleague if the situation 
deteriorated. In his own words:  
 
”During that long night, helplessly watching the patient struggle for life as her blood became 
darker and her veins more distended, the idea naturally occurred to me that if it were 
possible to remove continuously some of the blue blood from the patient’s swollen veins, put 
oxygen into that blood and allow carbon dioxide to escape from it, and then to inject 
continuously the now-red blood back into the patient’s arteries, we might have saved her life. 
We would have bypassed the obstructing embolus and performed part of the work of the 
patient’s heart and lungs outside the body.” (15)  
 
The story of ECMO cannot be described without mentioning the heart-lung machine or 
cardiopulmonary bypass (CPB). The anecdote above was the spark that later developed into 
years of research and finally doctor Gibbon’s screen oxygenator CPB, with which an atrial 
septum defect was successfully operated at Jefferson Hospital in Philadelphia USA in 1953. 
As the technique evolved, mortality during heart surgery declined from 50% in 1955 to 20% 
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in 1957, and in 1967, the CPB enabled doctor Christiaan Barnard to perform the first human 
heart transplant (16). The problem with the early CPB was that it caused haemolysis, 
thrombocytopenia, and bleeding after short periods of time, much due to the direct contact 
between oxygen and blood, which precluded it from long-term support. In the 1960s, a 
membrane lung oxygenator was developed which used a silicon rubber membrane to separate 
the gas and fluid elements. This enabled the apparatus to be used for days to weeks before 
major complications arose. The technique came to be called “extracorporeal membrane 
oxygenation”, to differ it from non-membrane oxygenators (17). In 1971, the first successful 
case of adult ECMO treatment was described, in a man with acute respiratory distress 
syndrome (ARDS) after a traffic accident (18-19). In 1975, the first successful neonatal 
patient with respiratory failure was treated by doctor Robert Bartlett, a man many people has 
come to refer to as “the father of ECMO” (20). The patient, an orphan to a Mexican mother, 
was named “Esperanza” (Spanish for “hope”; [21]). Similar to doctor Gibbon’s original 
thoughts in the 1930s, ECMO bought time in severe but treatable conditions that caused the 
heart or lungs to fail. The main differences between ECMO and a modern CPB are outlined 
in Table 1 below.  
 
Aspect CPB VV ECMO VA ECMO (peripheral) 
Cardiac bypass Full None Partial to full 
Heparin dose High Low Low 
Pump flow High As needed: low for 
decarboxylation, high 
for oxygenation 
As needed: low for decarboxylation, high 
for oxygenation 
Haematocrit Low Normal Normal 
Hypothermia Yes No (if needed) No (if needed) 
Haemodynamics Affected Minimally affected Affected 
Risk of side effects High (time 
dependant) 
Low Medium 
Body part with risk 
of low O2 saturation 
- - Possibly in the right upper body 
(differential hypoxia) and the cannulated 
leg (if no extra perfusion cannula is used). 
 
Table 1. Main differences between ECMO and a modern cardiopulmonary bypass.   
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2.3 MODERN ECMO TREATMENT 
Early ECMO devices carried a significant risk for thrombocytopenia and bleeding and 
required a high pressure to generate flow due to a high blood flow resistance (22). Roller 
pumps (as opposed to centrifugal pumps) were generally used, before modern non-porous 
hollow fibre devices with low flow resistance were introduced, safely allowing a centrifugal 
technique for prolonged periods of time (although different brands use slightly different 
techniques). Modern devices also use new materials and antithrombogenic surfaces such as 
heparin coating, further decreasing the risk of thrombosis and the need for anticoagulation. 
Most improvements have been gradual and differ between centres, which makes a distinct 
cut-off in time when ECMO has evolved into something new difficult. Modern ECMO 
treatment involves less sedation, spontaneously breathing patients (usually with mechanical 
pressure support or continuous positive airway pressure), extubated patients with a 
tracheostomy often able to communicate with the staff, increased mobilisation and less lung 
recruitment manoeuvres (23). This has altogether contributed to the relatively safe ECMO 
treatment we are familiar with today, with 15-35% mortality for severe respiratory failure (1, 
4). 
It is currently unknown whether the minimal ventilatory settings seen during ECMO 
treatment may reduce ventilator-induced lung injury and patient morbidity and mortality (8, 
24-25). It is further debated whether modern ECMO treatment reduces or increases net 
inflammation in the body (26-27) and what role inflammation plays in survival and long-term 
outcomes (13, 28). 
2.4 SCIENTIFIC EVIDENCE IN RESPIRATORY FAILURE 
In a 1979 randomised controlled trial (RCT), a 90% mortality was reported for ECMO in 
adult respiratory failure (29). Favourable results from the neonatal and paediatric world and 
the numerous case reports where ECMO was used as rescue therapy in severely hypoxaemic 
patients kept ECMO going over the years, despite the lack of high-quality studies (30).  It 
was not until the CESAR RCT in 2009 and the H1N1 influenza pandemic 2009-2010 that the 
interest for ECMO in adults with respiratory failure renewed, with early reports of a 
convincing 71-76% survival (3, 5, 31). Since then, the use of ECMO has increased steadily, 
especially in the adult population (1). In 2018 a new RCT was published (EOLIA trial; [4]). 
The trial was designed to test the benefit of early ECMO vs conventional treatment in severe 
ARDS. The study failed to show a significantly better 60-day mortality rate (hazard ratio 0.70 
compared to conventional treatment, 95% CI 0.47 -1.04, P=0.07).  Crossover from the 
conventional treatment group was high (28% of patients randomised to conventional 
treatment), and it has been questioned whether the goal to show an absolute mortality 
reduction of 20% was possible, given the low recruitment rate (32). Therefore, it remains 
controversial whether ECMO should be used early in ARDS, but its role as a salvage therapy 
in refractory cases is relatively well mounted (33).  
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2.5 ARDS AND CONVENTIONAL TREATMENT OPTIONS 
A common and feared clinical situation is acute respiratory distress syndrome (ARDS), 
characterised by refractory hypoxaemia with bilateral pulmonary infiltrates, not explained by 
left heart failure (34-35). ARDS accounts for 10% of ICU admissions globally and has a 
mortality of 40-50% in severe cases (36). ARDS may be triggered by several conditions, both 
pulmonary (e.g. pneumonia, aspiration) and non-pulmonary (e.g. sepsis, pancreatitis, blood 
transfusions, and trauma). Supplemental oxygen and mechanical ventilation (MV) are the 
cornerstones in the treatment of ARDS, but carry inherent adverse effects, such as oxygen 
toxicity and ventilator-induced lung injury (VILI). VILI is caused by oxygen toxicity and the 
unnatural mechanical power working on the lungs (barotrauma), and an increased 
inflammatory reaction in the lungs (37). In ARDS, so-called lung-protective ventilation is 
recommended with low tidal volumes and inspiratory pressures (38-39). This is however 
limited by how much hypercapnia, respiratory acidosis, and hypoxaemia the patient can 
tolerate.  
Further ventilatory options include high peak end-expiratory pressures (PEEP), recruitment 
manoeuvres and high-frequency oscillatory ventilation (HFOV). HFOV is a form of low-tidal 
volume ventilation which aims to prevent lung injury from overdistension and loss of 
recruitment. HFOV is sometimes used as a rescue therapy, especially in neonates, but has 
failed to improve survival on a group level in adults with moderate to severe ARDS (40-41). 
To enable controlled mechanical ventilation, patients are usually deeply sedated, and a 
neuromuscular blocking agent is commonly used. Other possible medical treatments include 
inhaled nitric oxide, inhaled prostacyclin and intravenous almitrine (4, 39). 
Another complementary approach is prone positioning, which improves ventilation/perfusion 
matching by addressing the heterogenous (dorsal) atelectasis and consolidation seen in ARDS 
(39). Prone positioning decreases mortality in moderate to severe ARDS and is not associated 
with any direct costs but is cumbersome for the hospital staff, which may explain why as few 
as 31% of patients receiving ECMO have had a trial with prone positioning (42). 
2.6 FOR WHOM IS ECMO USED? 
The principal indication for ECMO treatment is severe circulatory or respiratory failure 
refractory to the conventional treatment options mentioned above. After its introduction in the 
1970s, ECMO was primarily used in newborns with severe respiratory failure (e.g. persistent 
foetal circulation, congenital diaphragmatic hernia [CDH], meconium aspiration syndrome 
[MAS]) and subsequently in older children (22, 43).  As described above, ECMO has become 
standard of care for respiratory failure in adults in many centres despite a lack of sound 
evidence (30, 39).  
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Venoarterial ECMO is used as temporary support in severe circulatory failure, including 
when right heart failure develops during venovenous ECMO. In adults, severe cardiac failure 
after e.g. myocardial infarction or heart surgery is another common indication, to stabilise the 
haemodynamic situation until cardiac vessel catheterisation can be performed or as a bridge 
to recovery, mechanical assist device or transplant (22). ECMO for cardiopulmonary 
resuscitation (ECPR) has evolved as an alternative in refractory cardiac arrest, e.g. in cases 
with a witnessed cardiac arrest and bystander CPR, with a suspected reversible cause (e.g. 
myocardial ischemia). Several centres also treat patients with septic shock (1, 44) and 
perform ECMO in the pre-hospital setting, which anecdotally includes a French centre which 
has cannulated patients in the subway, on the streets of Paris and even in the Louvre museum 
(google “ECMO Louvre” for pictures).  
Other uses include ECMO as a bridge to lung transplant, ECMO to keep organs viable for 
donation after cardiac death and experimental uses such as ECMO as an artificial placenta in 
prematurity (45-46).  
A large registry held by the Extracorporeal Life Support Organization (ELSO) based in Ann 
Arbour, Michigan, USA, keeps track of North American and most international ECMO cases 
since 1990. To date (December 2018) more than 100,000 cases have been reported (1), and 
the evolution of the case mix can be seen in Figure 2. ELSO also publishes treatment 
guidelines to aid clinical decision making in patients receiving or being considered for 
ECMO treatment (47). 
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Figure 2. Proportional ELSO Registry case mix 1990-2018. Reprinted with permission (1). Note the 
proportional increase in adult patients starting around 2009. 
 
In neonates, the Oxygenation Index (OI) represents the level of hypoxaemia in the light of 
ventilatory support and is used as a help to identify patients eligible for ECMO treatment 
(typically patients with an OI >40 for >4 hours). OI is defined as FiO2 x 100 x mean airway 
pressure in cm H2O / post-ductal PaO2 in mmHg. In paediatric patients and adults, the ratio 
PaO2/FiO2 (PF ratio) is used in a similar way and represents the level of hypoxaemia. The PF 
ratio is used in the grading of ARDS according to the Berlin definition (35), with 200-300 
representing mild, 100-200 moderate and <100 severe ARDS (PaO2 in mmHg). The Murray 
score is another parameter commonly used to decide whether a patient is eligible for ECMO 
treatment, including four parameters: the degree of consolidation on chest x-ray findings, PF 
ratio, PEEP and lung compliance (3, 48). All three indices are clinical parameters from one or 
a few tests taken before or upon referral and sticks with a patient in many registries and 
databases. In reality however, they represent only a split-second view of the patient condition 
and cannot be used alone to describe a patient’s severity of disease.  
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2.7 ECMO CENTRE KAROLINSKA 
The ECMO Centre of the Karolinska University Hospital (ECK) treated its first patient in 
1987 and has since treated more than 1,000 patients. It’s considered a high-volume centre 
(49), with more than 30 cases annually since 2003 and ≥ 80 cases annually since 2010 
(Figure 3). Initially, the ECK only treated neonatal and paediatric patients. The first adult 
patient was treated in 1995, and since 2007 adult patients constitute the most numerous age 
group. 
The ECK differs somewhat to most other centres, most notably by being a dedicated ECMO 
ICU, i.e. only patients on ECMO are treated (most centres use ECMO on an “as needed” 
basis, in conjunction with other ICU patients), and the centre is a nation-wide referral centre 
for this indication. This has implications on staff training and experience since the whole 
ward is dedicated to the technology. The ECK has used minimal sedation and awake ECMO 
since the 1990s, and many patients were treated for long periods of time when ECMO 
internationally was seldom used more than 10-15 days (50-52). Cannulation is performed by 
a paediatric, vascular or cardiothoracic surgeon. The strategy for ventilator pressures, tidal 
volumes and fraction of inspired oxygen have been largely unchanged since the mid-1990s 
and includes a general reduction of inspiratory pressures within 3 hours from the 
commencement of ECMO in order to prevent further ventilator-induced lung injury. These 
settings are maintained until ECMO discontinuation. At this stage, the patients are ventilated 
conventionally with as low pressures and inspired fraction of oxygen as possible until 
breathing spontaneously (7, 50). 
Approximately 90% of the patients treated at the ECK suffer from respiratory failure or 
sepsis. No developed program for ECPR exist, and by tradition, another ICU at the hospital 
(the thoracic ICU) treats most adult patients with cardiac indications, primarily with 
perioperative cardiac failure. When paediatric or adult patients are treated for cardiac failure 
or ECPR at the ECK, ECMO is often used as a last-resort rescue therapy. Neonatal cardiac 
patients are however common, where ECMO is used as a bridge to surgery.   
Another aspect which may differ compared to other centres is the view on permissive 
hypoxaemia. The ELSO guidelines accept lower arterial haemoglobin oxygen saturations 
(SaO2 ≥ 80%) than those recommended by the ARDSnet for conventional mechanical 
ventilation (≥88%). At the ECK, values as low as 70% have been accepted for prolonged 
periods of time in selected patients (pulse oximetry measurements [SpO2] from the right ear, 
finger or nose complemented by arterial blood gas measurements; [38, 53-54]).  
This permissive hypoxaemia approach is accepted if no signs of tissue hypoxia are seen (i.e. 
inadequate oxygen delivery to the tissues). At the ECK, the protocol is generally to monitor 
lactate and pre-oxygenator venous oxygen saturation (SvO2) as rough measures of adequate 
tissue oxygenation. If lactate rises above 2.0 or SvO2 falls below 65%, with no other apparent 
explanation, this is considered a marker of possible tissue hypoxia and compensated by 
increasing ECMO flow, optimising cannula positioning and haemoglobin concentration (i.e. 
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red blood cell transfusions). The rationale for this is the oxygen delivery equation D’O2 = Q x 
(haemoglobin concentration x SaO2 x 1.34), where D’O2 is the oxygen delivery rate in 
mL/min, Q is the cardiac output in L/min (partly or fully substituted with extracorporeal 
circuit flow in VA ECMO) and SaO2 is the arterial oxyhaemoglobin saturation. Physically 
dissolved oxygen in the blood is neglected in the above equation.  
 
 
Figure 3. Patients treated at the ECMO Centre Karolinska from 1987 to 2013. 
 
2.8 SURVIVAL AFTER ECMO 
Since ECMO is a life support technique, survival is the main outcome parameter. The 
knowledge of short-term survival after ECMO is well-documented due to the ELSO registry 
(Table 2). It is well recognised that in-hospital survival outcomes vary according to diagnoses 
or indications for ECMO. For instance, the mean survival after ECMO for neonatal 
respiratory failure is 84% and within this group patients treated for meconium aspiration 
syndrome has a 3-month survival of 90% (55). In the other end of the spectrum, ECMO for 
cardiopulmonary resuscitation (ECPR) in adults has a mean survival to discharge of 29% (1).  
Furthermore, like many complex, resource-intensive therapies, ECMO patients have better 
outcomes at centres which perform more cases annually (49).  
Few publications have reported data on long-term survival, and those that existed prior to this 
doctoral project had, for the most part, had short time horizons, small study groups or focused 
on cardiac disease (3, 56-58). Iguchi and colleagues presented a study on long-term survival 
and causes of late death in ECMO-treated children, 39% of whom were cardiac patients (as 
opposed to <10% at the ECK; [55]). They reported high mortality within the first 90 days 
after ECMO and suggested a cut-off at this point in time to define late survival. Patients who 
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were alive at this stage generally had a very good long-term survival, if treated for a 
reversible condition such as infectious disease or meconium aspiration syndrome. For MAS, 
Iguchi reported a “conditional” 5-year survival rate of 98%, i.e. 98% of the patients who were 
alive at 90 days, were alive after 5 years. Hsu and colleagues presented epidemiological data 
from the use of ECMO in Taiwan 2000-2010 (56). 3,969 patients were included, and the 
overall survival to discharge was 33% (compared to the overall reported ELSO survival of 
56%). Furthermore, patients had ongoing mortality after discharge, and less than 70% of the 
survivors treated for respiratory failure were alive 5 years after treatment.  
 
Patient group 
 
Total runs 
  
Survived treatment 
  
Survived to discharge or 
transfer 
Neonatal 40,446   
Pulmonary 30,934 84% 73% 
Cardiac 7,794 64% 42% 
ECPR 1,718 66% 41% 
    
Paediatric 23,228   
Pulmonary 8,820 67% 58% 
Cardiac 10,462 68% 52% 
ECPR 3,946 57% 42% 
    
Adult 37,231   
Pulmonary 16,337 66% 59% 
Cardiac 15,942 55% 42% 
ECPR 4,952 38% 29% 
    
TOTAL 
  
100,905 
 
68% 
 
56% 
  
Table 2. ELSO Registry International Summary July 2018 (1). 
 
2.9 COGNITIVE FUNCTIONS AFTER ECMO 
Critical illness may result in significant long-term cognitive dysfunction (CD). 9-56% of 
patients have been reported to have some form of CD 2-8 years after ICU care (59). There are 
many risk factors for this, including multi-organ failure, inflammatory cytokines, 
hypotension, brain hypoxia, and blood glucose abnormalities. Furthermore, anaesthesia and 
sedating drugs have been reported as possible risk factors for delirium and long-term CD 
(60).  
Patients treated with ECMO have several risk factors for CD from both the pre-ECMO period 
(with severe cardiac or respiratory failure and a failing conventional treatment) and the 
ECMO period itself. In children, neurodevelopmental disabilities and an increased need for 
special aid in school have been reported (61). ECMO specific risks include altered 
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coagulation, haemodynamics, and prolonged immobilisation and hospitalisation (62). 
Regional oxygen and blood flow imbalance and direct embolisation to the brain may 
constitute specific risks during VA ECMO. Moreover, many patients treated with ECMO are 
exposed to permissive hypoxaemia, which by several authors has been linked to CD (63-64). 
Meanwhile, ECMO treated patients may benefit from a more lung-protective ventilation and 
minimal sedation, possibly reducing the systemic inflammatory response (27, 54, 62).  
Improved cognitive functions have been reported at least during the first year after discharge 
from the ICU, but little data exist over time periods longer than two years (13). One study 
showed attention, concentration, and memory deficits in 24% of ARDS patients six years 
after treatment (6 of 46 patients were treated with ECMO, but their results were not reported 
specifically; [65]). When investigating the same cohort two years later, 9% had mild to 
moderate cognitive impairment (66). In another study, neurologic outcomes in 28 ECMO-
treated patients were presented on average 5 years after treatment (12). Clinical impairment 
was seen in 43%, and patients with intracranial lesions had worse cognitive outcomes. 
Researchers from the ECMO Centre Karolinska investigated seven H1N1 influenza survivors 
three years after discharge and found no evidence of cognitive dysfunction (54). Although the 
cohort was small, no association between hypoxaemia during ECMO and cognitive 
dysfunction was found. 
2.10 QUALITY OF LIFE AND LONG-TERM SIDE EFFECTS AFTER ECMO 
In patients with a history of ARDS, the long-term burden is prominent and well-described 
(13, 62, 67). This involves several organ systems, including the lungs, the muscular system, 
and the central and peripheral nervous systems. Many deficits improve in the first years after 
discharge, but some degree of pulmonary dysfunction, mood disorders, and muscle weakness 
seem to prevail even five years after treatment (14, 67-68). 
In the ECMO population, most studies published prior to the present doctoral project had 
median follow-up times of 6-17 months after treatment (14), and a single study (also 
conducted at the ECK) investigated patients after 26 months (50).  
Although comparing studies is cumbersome, ECMO treated patients seem to score similarly 
on the physical and the mental component scores of the well-validated quality-of-life 
questionnaire Short form 36 as conventionally treated patients (SF-36; [14]). Furthermore, the 
incidence of mood symptoms may be lower in ECMO treated patients and pulmonary 
function, namely a reduced diffusion capacity for carbon monoxide (DLCO), has been 
reported with similar results for both groups (14).
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3 AIMS 
The overall intention of this doctoral project was to evaluate life after ECMO. What is the 
survival and survivorship ≥ 3 years after leaving the ECMO unit? 
 
The specific aims were: 
1. To evaluate the long-term survival and causes of death after treatment with 
ECMO for respiratory failure and sepsis in adults (≥18 years). 
 
2. To evaluate the long-term survival and causes of death after treatment with 
ECMO in children (<18 years). 
 
3. To investigate the long-term cognitive functions and frequency of 
cerebrovascular lesions in adult ECMO survivors treated for respiratory failure. 
 
4. To assess the long-term quality of life, pulmonary morphology and function, 
walking capacity and level of post-traumatic stress, anxiety, and depression 
after ECMO treatment for respiratory failure in adults. 
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4 ETHICAL CONSIDERATIONS 
Full ethical approval was granted for this doctoral project (Stockholm regional ethical review 
board no. 2013/2259-31/4 for study I and II, 2013/2258-31/1 for study III and IV). The 
follow-up investigations (study III and IV) were registered at clinicaltrials.gov 
(NCT03031275). 
The survival analyses (study I and II) were conducted as retrospective registry studies, with 
no involvement or contact with the patients. The main concern was that sensitive patient data 
would leak to a third party. Personal identification data were for this reason deidentified, and 
all results were presented on a group basis except when causes of death were presented in 
study I (supplemental digital content 2). In this case, to minimise the possibility of 
backtracking, the patients’ ages were grouped by decades. 
The follow-up investigations underlying study III and IV required more careful reflection and 
were performed after collecting each patient’s individual written consent, according to the 
guidelines presented by the Swedish Data Protection Authority 1998:204 (Datainspektionen, 
“Personuppgiftslagen”). The database was deidentified in the same way as the survival 
analyses, and results were generally presented on a group basis. When publishing study III, 
individual results were included in supplementary digital content 3. This was in line with the 
written consent we had from patients (freely translated to “either fully anonymised on a group 
basis or fully deidentified”) but was not stated explicitly in the ethical application. To 
minimise the risk of identifying individuals, the data was decoded with age groups (≤40 or 
>40 years old), diagnosis (pneumonia vs non-pneumonia) and follow-up time (<10 or ≥10 
years). Another risk for the individual patient was radiation from the computed tomography, 
which the patients were informed about and consented to. It is my sincere hope that each 
patient felt they were given the chance to, as far as reasonably possible, understand and 
contemplate the risks and benefits of participating before deciding. Possible benefits included 
the thorough investigations made (with both personal and group results presented to the 
patients) and an opportunity to talk about and increase their understanding of ECMO and the 
experiences they had been through. 
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5 METHODS 
5.1 OVERVIEW OF METHODS 
An overview of the study methods is presented in Table 3 below. 
 
Study Design Study population Aim No. of 
participants 
Statistical 
methods 
I Retrospective 
registry study 
Adult patients (≥18 yrs) 
with respiratory failure 
or sepsis treated 1995 – 
2013 
To study the long-
term survival and 
causes of death 
255 Kaplan-Meier 
method, Log-
rank (Mantel-
Cox) test, Cox-
proportional-
hazards model 
II Retrospective 
registry study 
Neonatal patients 
(cardiac/respiratory) and 
paediatric patients (-17 
yrs, respiratory) treated 
1987 – 2013 
To study the long-
term survival and 
causes of death 
400 Kaplan-Meier 
method, Log-
rank (Mantel-
Cox) test 
III Retrospective 
cohort 
Long-term adult 
survivors (respiratory 
failure) treated 1995 - 
2009 
To evaluate long-
term cognitive 
dysfunction and 
brain lesions 
 
38 Mann-Whitney 
U test 
IV Retrospective 
cohort 
Long-term adult 
survivors (respiratory 
failure) treated 1995 - 
2009 
To describe the 
long-term quality 
of life, mood 
disorders, lung 
function and 
morphology, and 
6-minute walk 
distance 
38 Descriptive 
statistics (mean, 
SD and median, 
IQR), 
Spearman’s rank 
correlation test 
Table 3. Overview of study methods. 
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5.2 STUDY DESCRIPTIONS 
Study I and II were retrospective registry studies using the Swedish causes of death registry 
(69). All patients with a Swedish personal identification number treated at the ECMO Centre 
Karolinska from the centre’s foundation in 1987 to December 2013 were cross-matched with 
the registry, and emigration status was obtained from the population registry (Swedish Tax 
Agency). Study I (adults) included patients with respiratory failure or sepsis since these 
indications constitute 90% of the patients treated at the centre. Cardiac (n=5) and ECPR 
(n=28) cases were excluded, as were non-Swedish citizens treated at the centre (no personal 
identification number, n=25). Study II (children 0-17 years old) excluded paediatric cardiac 
patients (n=8) and ECPR patients (n=40) for the same reason as described above, while 
neonatal cardiac patients (n=17) were included since this group has historically been common 
at the centre (usually treated while awaiting cardiac surgery). Non-Swedish citizens were also 
excluded (n=85). 
The Kaplan-Meier method was used for survival calculations, and patients were grouped 
according to modified ELSO criteria. In study I, new groups were created altogether, while 
minor modifications were done in study II. Survival status and causes of death were obtained. 
Causes of death were registered according to ICD-9 or ICD-101 and were written by the 
physician in charge either at the hospital or in general practice for patients who died at home. 
A 90-day cut off was used to define late death, based on a previous study which showed high 
mortality in the first 90 days after treatment (55). Conditional survival rates were calculated 
(i.e. survival rates in patients who were alive 90 days after decannulation) to describe long-
term survival in the group that survived the first critical period. In Study I, individual factors’ 
influence on the patients’ survival were evaluated using the Cox proportional-hazards model. 
The general hypothesis for study I and II was that patients with a fully reversible condition 
who survived the initial critical months after treatment would have excellent long-term 
survival. 
Study III and IV were follow-up investigations in a cohort of adult survivors. The first adult 
patient was treated in 1995, and consecutive survivors living in Sweden were contacted by 
mail and phone. Eligible survivors were approached (January 2014), and patients who agreed 
to participate were investigated during a day at the hospital, including magnetic resonance 
imaging (MRI) of the brain, neurocognitive tests2 (70-75), high-resolution computed 
tomography (HRCT) of the lungs, pulmonary function testing (static and dynamic 
spirometry) and the 6-minute walk test (6MWD). Furthermore, patients were interviewed, 
and self-report forms were filled out to evaluate general quality of life (Short form 36; [76]), 
                                                 
1 ICD = international classification of diseases, World Health Organisation. In Sweden, ICD-10 replaced ICD-9 
in January 2011. 
2 Cognitive tests consisted of the Wechsler Adult Intelligence Scale 4th edition, the Wechsler Memory Scale 3rd 
edition (subtests), Rey Auditory Verbal Learning and Complex Figure Test, Free and Cued Selective and 
Reminding test, and the Delis–Kaplan Executive Function System (70-75). 
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respiratory-specific quality of life (St George’s Respiratory questionnaire; [77]), symptoms of 
anxiety and depression (Hospital Anxiety and Depression Score [HADS]; [78]) and 
symptoms of post-traumatic stress disorder (PTSD, Trauma Screening Questionnaire [TSQ]; 
[79]). After investigating 35 patients, it was clear that the group was quite heterogeneous, and 
it was decided that patients treated for non-respiratory conditions and patients with a 
congenital mental disability should be excluded (n=4/35, resulting in 31 included and 
investigated patients). At this stage, the next survivors in line to be asked had already been 
investigated by a colleague three years after treatment (unpublished data at the time, cognitive 
results were later published separately; [54]). These patients were approached, and seven 
patients were added to the present cohort, with missing investigations completed when 
possible. In this way, the final cohort size became 38 patients.  
Patient selection and investigation coherence are presented in Figure 4 based on the final 
inclusion and exclusion criteria (n=31+7=38). 
  
 24 
 
Figure 4. Flowchart showing patient inclusion and exclusion, patients lost to follow-up and testing 
coherence for study III and IV. Reproduced from study III and IV. 
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Interpretations of individual investigations were done by trained specialists (e.g. radiologists, 
neuropsychologists, a physiotherapist for the 6MWD, a nurse certified in SF-36 and SGRQ 
interpretation) and disagreements were generally resolved by consensus between specialists. 
All investigators were blinded from any patient details but were aware of the presence of 
ECMO treatment. Patient charts were reviewed for clinical information, including hourly 
registered individual parameters (e.g. pulse oximetry oxygen saturations, mean arterial 
pressures, lactate levels, and the PEEP and FiO2 used during ECMO treatment). Since some 
patients were treated for long periods of time, a ten-day observation period was decided upon 
to represent the ECMO treatment period (if treated <10 days, the whole treatment period was 
included). Pulse oximetry oxygen saturation values (SpO2) defined hypoxaemia as a median 
SpO2 <93% during the observation period (measured by peripheral pulse oximetry from the 
right ear, nose, or finger). This was in line with the methods used in the H1N1 cohort (54). 
Patients who, according to this definition, were hypoxaemic during the ECMO observation 
period were analysed separately in study III.   
The main outcome parameters in study III were three indices representing global cognitive 
function (full-scale intelligence [FSIQ]), memory function (memory index) and executive 
function (executive index). The indices were created by comparing individual scores with 
age-matched healthy populations. These were presented using the IQ standard scale (normal 
mean = 100; SD 15). We did not use a strict definition of cognitive dysfunction since no 
widely accepted definition exists (59). Instead, group medians (IQR) and the number of 
patients with scores 1 and 2 SD below the group mean were presented. The hypothesis was 
that cognitive functions would generally be normal in ECMO treated patients, on par with a 
healthy normal population, and that hypoxaemia per se would not be associated with 
cognitive dysfunction if tissue hypoxia was avoided.  
In study IV numerous outcome parameters were investigated. The main parameters of 
interest were the SF-36 physical and mental component scores, the SGRQ total score, 
diffusion capacity for carbon monoxide (DLCO, presented in % of expected normal value) 
and the extent of lung parenchyma pathology (presented in % of total lung parenchyma). The 
hypothesis was that quality of life, pulmonary function, mood levels and diffusion capacity 
(DLCO) after ECMO treatment would be reduced but similar to conventionally treated 
ARDS patients.  
  
 26 
5.3 STATISTICAL METHODS 
Survival was depicted using the Kaplan-Meier method, and the Log-rank (Mantel-Cox) test 
and Log-rank test for trend were used for the comparison of survival curves (study I and II). 
The Cox proportional-hazards model was used to evaluate the influence of covariates on 
survival in study I.  
In study III, Mann-Whitney U tests were used to compare the IQ index scores between 
groups. In study IV Spearman’s rank correlation test was used for evaluation of the 
correlation between outcome parameters of interest. Median or mean values for lung 
volumes, used in previous reports (3, 62, 67), were not calculated due to the heterogeneity of 
the data since the mean of mixed pathologically high and low values can be a normal value. 
Due to the methodological limitations of study III and IV and the small cohort size, we chose 
not to statistically test the reported findings further. P-values less than 0.05 were considered 
statistically significant. 
Unless otherwise stated data were expressed as median (IQR). 
Statistics were evaluated by Graph Pad InStat version 3.10 (Graph Pad Software, San Diego, 
USA) for study I, II, and IV. R software version 3.4.2 (R Foundation for Statistical 
Computing, Vienna, Austria; http://www.r-project.org) was used for all statistical analyses in 
study III. 
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6 RESULTS 
The most important findings are presented here. For all results, please refer to the full-text 
manuscripts with appendices enclosed at the end of this book. 
6.1 SURVIVAL 
In the survival studies (study I and II), there was no loss to follow-up. Median follow-up 
times were 7.8 years (mean 9.3) in neonatal patients, 5.6 years (mean 7.6) in paediatric and 
4.4 years (mean 6.0) in adults. Median age was 2 days, 3 years and 46 years, respectively, and 
median EMCO treatment time was 6, 7 and 8 days, respectively. 
Immediate survival after ECMO treatment was 84% in neonates, 74% in paediatric patients 
and 66% in adults (Table 4). Some patients, however, diseased shortly after decannulation3 or 
before discharge to another hospital. 76%, 66%, and 55% respectively survived to 90 days 
after treatment, meaning that 9% of neonatal (21/222), 10% of paediatric (10/100) and 17% 
of adult survivors (29/168) died in the first 90 days after treatment. For most diagnostic 
groups, the survival curves plateaued after this point in time (Figure 5 A-B), indicating a high 
survival in the group that survived the first 90 days after treatment. Meconium aspiration 
syndrome and congenital diaphragmatic hernia were the most common neonatal diagnostic 
groups, while infections, namely pneumonia, were most common in paediatric patients and 
adults. 
  
                                                 
3 Decannulation = discontinuation of ECMO by turning off the pump and retracting the cannulas from the 
vessels. 
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Patient group Survived 
treatment 
Survived to 
discharge 
90-day 
survival 
5-year 
survival 
5-year survival if 
alive at 90d 
Neonatal 84% 80% 76% 72% 94% 
MAS 100% 100% 99% 99% 100% 
CDH 83% 70% 68% 55% 77% 
Congenital heart disease 67% 67% 58% 50% 86% 
Paediatric 74% 68% 66% 61% 91% 
Bacterial pneumonia 83% 70% 66% 54% 82% 
Viral pneumonia 76% 76% 76% 76% 100% 
Other respiratory 63% 63% 63% 58% 92% 
Adult 
(n=255) 
66% 64% 55% 47% 87% 
Bacterial pneumonia 69% 66% 58% 51% 88% 
Viral pneumonia 65% 65% 61% 3YS: 57% 3YS: 93% 
Other respiratory 73% 73% 47% 40% 86% 
 
Table 4. Survival numbers for the three age categories and selected diagnoses after ECMO treatment 
(i.e. decannulation), after discharge from the Karolinska University Hospital, 90 days and 5 years 
later. For adult patients with viral pneumonia, the follow-up time was <5 years, and 3-year survival 
(3YS) is therefore presented. MAS = meconium aspiration syndrome; CDH = congenital 
diaphragmatic hernia. Reproduced from study I and II. 
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Figure 5. Kaplan–Meier survival estimates for selected diagnostic groups. In A, the initial descending 
part represents deaths during treatment (t0 = decannulation from ECMO treatment, diseased or alive). 
Panel B shows survival in patients who were alive at 90 days (i.e. t0 = 90 days after decannulation). 
Note that the curve for meconium aspiration syndrome (MAS) is hidden at 100% in panel B.  
CDH = congenital diaphragmatic hernia. Reproduced from study I and II. 
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Twenty-three late deaths (>90 days after treatment) appeared in the neonatal and paediatric 
cohorts (Table 5). Of these, 78% occurred within the first 3 years after treatment, and 12/14 
neonatal patients had CDH (died from severe underlying main disease n=9, never recovered 
n=1, unknown n=2). In adults, 17 late deaths occurred, 94% of which occurred within 3 years 
after decannulation. 
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Cause n,  
neonatal/paediatric 
n, 
adults 
Comment 
Never recovered 2 1  
Died from severe 
underlying main disease 
9 3 Congenital diaphragmatic hernia (CDH; n=9), 
cystic fibrosis (n=2), interstitial lung disease 
(n=1). 
Malignancy 3 - All known when ECMO was initiated. 
Sepsis 1 - Aspiration tendency. 
Intoxication - 3 Two had a known intoxication history. 
Common societal causes - 6 
Metastatic 
Cancer (n=1), ischemic heart disease (n=1), 
stroke (n=1), pancreatitis (n=1), 
sepsis (n=2; one acquired influenza with a 
complicating pneumonia). 
Miscellaneous 3 2 Children: encephalitis (n=1), persistent foetal 
circulation (n=1), immunodeficiency (n=1). 
Adults: immune disease (n=1), unspecified kidney 
failure (n=1). 
Unknown 
 
5 2  
Table 5. Causes of late death (>90 days after treatment). Reproduced from study I and II. 
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6.2 SURVIVORSHIP 
In study III and IV, 38 patients were investigated in median 9.0 years after treatment (mean 
9.6, range 3.1-17.1). Demographic data and clinical characteristics are shown in Tables 6 and 
7. 
 
Variable All patients (n=38) 
Age (yrs) 39 (24-52) 
Sex, male / female 63% / 37% 
Pre-existing condition  
None 26% (10/38) 
BMI>30 50% (17/34)a 
Cardiovascular disease 8% (3/38) 
Pulmonary disease 18% (7/38)b 
Diabetes mellitus 8% (3/38) 
Immunodeficiency 5% (2/38)c 
Other 13% (5/38)d 
Smoking exposition  
Never smoker 55% (21/38) 
<20 pack years 26% (10/38) 
>20 pack years 18% (7/38) 
Smoking at follow-up 
 
11% (4/38) 
 
Table 6. Demographic data at the time of ECMO treatment on patients included in study III and IV. 
Results are expressed as median (IQR) or % (n). Reproduced from study III and IV. 
a  Note that a high BMI in some cases may represent excess fluids from severe illness 
and its treatment. Median BMI (IQR): 30 (25-31). n (total) = 34 due to missing data. 
b  5 asthma, 1 granulomatosis with polyangiitis (Wegener’s, undiagnosed prior to ECMO 
treatment), 1 had undergone a curative lobe resection for small-cell lung cancer.  
c  1 common variable immunodeficiency (CVID) with IgA deficiency, 1 suspected but 
unknown immunodeficiency. 
d  1 Crohn’s disease, 1 ulcerous colitis, 2 severe depression/anxiety, 1 pregnancy. 
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Variable All patients (n=38) 
Diagnosis  
Bacterial Pneumonia 63% (24/38) 
Viral Pneumonia (H1N1) 18% (7/38) 
Other pulmonary indication 8% (3/38)a 
Non-pulmonary 11% (4/38)b 
Durations (days)  
Mechanical ventilation 
before ECMO 2 (1-6) 
ICU before ECMO 3 (1-7) 
ECMO treatment 11 (7-23) 
Mechanical ventilation, total 31 (15-44) 
ICU, total 37 (23-57) 
Hospital time, total 54 (30-114) 
ECMO mode  
Venovenous (VV) 71% (27/38) 
Venoarterial (VA) anytimec 29% (11/38) 
Pre ECMO PaO2/FiO2 
 
mmHg: 51 (43-58) 
kPa: 7 (5-8) 
Table 7. Clinical characteristics of patients included in study III and IV. Results are expressed as 
median (IQR) or % (n). Reproduced from study III and IV. 
a  1 lung bleed due to granulomatosis with polyangiitis (Wegener’s, VV/hypoxaemia), 1 
aspiration pneumonia after oral drug intoxication (VV/hypoxaemia), 1 asthma 
exacerbation (VV/hypercapnia). 
b  1 developed ARDS after severe eclampsia and post-caesarean section bleed (VA 
ECMO, indication: hypoxaemia), 1 ARDS after septic abortion (initially VV, 
converted to VA ECMO, hypoxaemia), 1 multiple trauma (VV/hypoxaemia), 1 septic 
shock after neck infection (VV/hypoxaemia). 
c Includes patients initially treated with venovenous ECMO, and later converted (n=4) 
and vice versa (VA-VV, n=2). 
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6.2.1 Study III 
Twenty-eight patients had full testing performed, while seven patients were tested for 
memory functions only (due to a short formal education <9 years; Figure 4). Three patients 
were not tested whatsoever (logistical problems n=1, inadequate language comprehension 
n=2). The median FSIQ was 97 (IQR 86–104) and was within 1 SD in 79% (22/28 tested 
patients). Median memory function index was 101 (IQR 89–109), with one patient below 1 
SD from the mean, and the median score on the executive function index was 104 (IQR 99–
108), with two patients below 1 SD from the mean. Cerebrovascular lesions (CVL) were 
present in 37% (14/38; 64% in patients treated with VA ECMO).  In the group with CVL, IQ 
scores were lower in all three domains, with significantly lower memory index (p=0.03) and 
executive index (p=0.02). No significant differences were found in either domain between 
patients with hypoxaemia during ECMO and patients without (Figure 6), including when 
testing an alternative definition of hypoxaemia post-hoc (defined as ≥12 hourly registrations 
or whole observation period median SpO2 ≤85%). 
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Figure 6. Neurocognitive test results from study III representing different cognitive domains based on 
MRI findings and hypoxaemia status during the ECMO observation period. Normal mean is 100 and 1 
SD is 15 according to the intelligence quotient (IQ) standard scale. Note that only memory function 
was tested in some patients and the low sample size in B and D. Individual results are plotted as faded 
grey dots, and outliers are presented as triangles. The figure was created using ggplot2 for R statistics 
(Wickham, Ggplot2, Elegant Graphics for Data Analysis. New York, NY, Springer-Verlag, 2009).  
A, Hypoxaemic group, no brain lesion; n = 19, full testing: n = 13.  
B, Non-hypoxaemic group, no brain lesion; n = 5, full testing: n = 4.  
C, Hypoxaemic group, brain lesion; n = 9, full testing: n = 8.  
D, Non-hypoxaemic group, brain lesion; n = 5, full testing: n = 3.  
Mann-Whitney U tests were performed to test the statistical difference between the groups for each 
cognitive domain. For patients with no lesions (A vs B), p values were 0.69 (full-scale IQ), 0.77 
(memory index), and 0.83 (executive index). For patients with brain lesions (C vs D), p values were 
0.50 (full-scale IQ), 0.50 (memory index), and 1.0 (executive index). Reproduced from study III. 
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6.2.2 Study IV 
Quality of life was tested in 37/38 patients and was reduced in most domains of the SF-36, 
and all domains of the SGRQ, but comparable to conventionally treated ARDS patients 
(Figure 7 A-B). Symptoms of post-traumatic stress were seen in 14% (5/36). Possible anxiety 
and depression were seen in 22% (8/36) and 14% (5/36), respectively. Approximately half of 
the patients (19/36) had a normal quality of life and no self-reported depression or anxiety 
any time after discharge. Patients treated with ECMO ten days or more were overrepresented 
in the lower ends of SF-36, SGRQ and anxiety/depression scores. 51% of patients were back 
to work or studies one year after discharge (median time 6 months), and 22% (8/37) were not 
working or studying at follow-up (two of whom were not working before ECMO). 
Lung function was normal in 37% of patients (14/38), primarily obstructive in 13% (n=5) and 
primarily restrictive in 21% (n=8). Many patients had non-ECMO-related risk factors for 
obstructive or restrictive disease (5/5 with signs of obstructive disease and 3/8 with signs of 
restrictive disease). Diffusion across the blood-gas barrier, assessed using the diffusing 
capacity for carbon monoxide (DLCO), was reduced in 47% of the patients. 
In 82% of patients, some degree of residual pathology was seen on HRCT of the lungs (>1% 
parenchymal damage), and the mean damage was 7% (range 0–44%). Parenchymal damage 
correlated (Figure 8 A-B) with days on ECMO and total days with mechanical ventilation 
(r=0.55, p<0.001 and r=0.72, p<0.001), and with SF-36 physical component score (r=-0.47, 
p=0.004), SGRQ total score (r=0.57, p<0.001) and DLCO (r=-0.57, p<0.001). 
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Figure 7. Quality of life results in comparison. A: Short form 36, B: St George’s Respiratory 
Questionnaire. CMV = conventional mechanical ventilation (i.e. not ECMO). Reproduced from study 
IV. 
 
  
 
Figure 8. Spearman’s rank correlations of lung parenchymal damage and quality of life (A) and time 
with mechanical ventilation (B). Reproduced from study IV. 
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7 DISCUSSION 
In this thesis, long-term survival and survivorship were investigated with registry studies 
(study I and II) and follow-up investigations (study III and IV).  
7.1 GENERAL DISCUSSION 
7.1.1 Study I and II 
There was high initial mortality, especially in the first three months after ECMO treatment. 
This is in line with the general ICU population and previous studies (55, 80-81), but is 
nevertheless important since many centres and the ELSO registry report survival to discharge 
only. If on the other hand, a patient survives to 90 days after treatment and was treated for a 
reversible condition such as meconium aspiration syndrome or an infection, long-term 
survival was good, with a principally plateaued survival curve. There was no unexplained 
accumulation of deaths years after treatment which would indicate an ECMO caused 
mortality. For most groups, survival to the 90-day endpoint was prognostic of 5 and 10-year 
survival, similar to what has been found in ICU treated patients in general (80, 82). 
Not surprisingly, survival differed between diagnoses and was poor in patients with severe 
co-morbidities (e.g. CDH patients and paediatric patients with cancer). In study I, age and 
cannulation group were linked to overall mortality in adults, but not to mortality in patients 
who survived to 90 days after treatment. Cannulation itself was probably not the main cause 
for this. Rather, a venoarterial cannulation and especially the need to convert from VV to VA 
ECMO represents a more severe cardiorespiratory failure not sufficing with or failing to 
improve despite venovenous ECMO. Age was linked to mortality only when the group with 
full data (PF ratio available) was analysed (p=0.04), and not when all 255 patients were 
analysed (p=0.10). Since missing PF ratio data was arbitrary, we consider the latter non-
significant result more reliable since it’s based on more patients. 
Causes of death, although a rough measure (see section 7.2.1), indicated that patients mainly 
died from a severe underlying disease, common societal causes or that the patient never fully 
recovered from the condition requiring ECMO treatment. It was however worrisome that 
three patients died from intoxications. Two of these patients had a history of self-incurred 
intoxications (one patient had an alcohol/drug dependence and one suffered from paranoid 
schizophrenia), but it is nevertheless sad that society, after long periods of intensive care 
treatment and rehabilitation, could not help these individuals with their underlying issues. 
When interpreting reports from the ELSO registry, one must remember that it constitutes data 
from many centres, which in turn may differ in size, experience, case mix etcetera. Moreover, 
the meaning of “survival to discharge” may differ vastly between centres. At the ECK, 
survival to discharge indicates discharge from the Karolinska University Hospital, which in 
turn means different things depending on the patient’s home city. For patients admitted from 
other hospitals outside Stockholm, discharge often meant that they were sent back to the ICU 
they were admitted from, while local patients were generally discharged from a normal ward 
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within the hospital to a rehabilitation unit or even home. Needless to say, the 3-month 
prognosis was probably inferior in the former group.  
Comparing survival between centres needs careful consideration. Among other things, the 
mix of patients (age, diagnosis, severity of disease, contraindications), timing of ECMO 
institution (and decannulation), centre experience, volume and coherence with ELSO 
guidelines may differ. Furthermore, as ECMO, ventilator and general ICU management have 
evolved over the years, it may be misleading to compare a cohort treated in the 1990s with 
patients treated today. We chose not to compare e.g. pre and post-millennial survival mainly 
since the changes in equipment and approaches to ECMO treatment have been gradual and 
during periods there has been a significant overlap. Furthermore, the general mix of patients 
at the ECMO Centre Karolinska may have differed over time. It is reasonable to believe that 
the number of patients where ECMO was tried as a last resort salvage therapy was higher 
during the early years of ECMO. This was a time when the technology was still considered 
experimental by many, and ELSO guidelines were less explicit and evidence-based.  
7.1.2 Study III and IV 
The follow-up investigations indicated problems in life years after ECMO on par with what 
has been described in conventionally treated ARDS patients, although the studies were not 
designed to compare ECMO to CMV (see section 7.2.2).  
Normal cognition was seen in the group with normal brain imaging (study III), although we 
could not present pre-illness cognitive functions. It is possible (but unlikely) that included 
patients’ baseline IQ could have been above the general average, meaning that a median IQ 
of 100 actually represented a reduction in the present cohort. Memory and executive 
functions were significantly reduced in patients with brain lesions, as previously reported 
(12). Brain lesions were common, especially in the VA ECMO group. In the published 
literature, there’s a large discrepancy between reported CVL prevalence when brain 
radiography is used when symptoms occur (5.3-5.4%; [83-84]) and routinely screened 
patients (16.4% in ECMO patients vs 7.6% in conventionally managed patients; [85]). The 
latter was supported in a recent study which reported CVL in 10.7% of ECMO patients upon 
admission, and a further 5.2% during ECMO treatment (86). Interestingly, the recent EOLIA 
RCT reported a similar haemorrhagic stroke prevalence in the ECMO (2%) compared to the 
non-ECMO group (4%), and significantly fewer ischemic strokes in the ECMO group 
(absolute risk reduction −5%, 95% CI −10% to -2%; [4]). No screening protocol was used in 
this trial (i.e. CT was used only if symptoms occurred).  
Hypoxaemia may cause tissue hypoxia, including hypoxic brain damage resulting in 
cognitive dysfunction (54). At the ECMO Centre Karolinska, arterial blood oxygen 
saturations (SaO2) of 70-80% have been accepted for long periods of time, as long as lactate 
stays low and pre-oxygenator mixed venous saturations high (i.e. permissive hypoxaemia 
with the assumption of no tissue hypoxia). Due to the inherent limitations in study III, 
including how hypoxaemia was defined (see section 7.2.2), the effects of hypoxaemia on 
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cognitive function remain unclear, although we have shown that patients with prolonged 
hypoxaemia may have normal cognitive functions years after treatment. 
The reductions in quality of life spanned across most domains but were similar to reported 
findings in conventionally treated ARDS survivors (study IV). Patients treated with ECMO 
ten days or more were over-represented in the worse ends of SF-36, SGRQ and mood 
symptom scores, which is expected since these patients probably represent more complex 
cases needing long treatment times to get better. The level of lung parenchymal damage 
correlated with a reduced quality of life and DLCO, and with time on ECMO and mechanical 
ventilation. Although perhaps not overly surprising, this may constitute a factor worthy of 
future evaluation as a marker for long-term sequelae after treatment. It is possible that the 
correlation with mechanical ventilation time represents VILI, which is supported by the 50% 
anterior location of parenchyma damage, but this remains speculative. 
Although not directly comparable, the present findings support the notion that ARDS 
survivors irrespective of CMV or ECMO treatment have a reduced quality of life even 3-17 
years after treatment. When weighing the results of three comparative studies, quality of life 
was similar or slightly better after ECMO vs CMV (14). Comparing ECMO patients with 
CMV is cumbersome since the “perfect” RCT has yet to be done. Problems include very low 
recruitment rates and that many clinicians believe it is unethical to keep a patient randomised 
to CMV when the patient is dying and could possibly be saved with ECMO treatment. The 
latter aspect results in a high crossover from the CMV to the ECMO group (28% in the recent 
EOLIA trial). In the aftermath of the EOLIA trial, it has even been questioned whether 
another large RCT of ECMO for severe ARDS will ever happen (32, 87). 
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7.2 WEAKNESSES AND DIFFICULTIES 
A general weakness of all four studies was their retrospective nature and lack of matched 
control groups.  
7.2.1 Study I and II 
In study I and II, the majority of patients were treated many years ago with intensive care and 
ECMO treatment of the time and may not be fully representative of patients treated today. 
Median (IQR) treatment dates for adult patients (study I) was February 2005 (November 
2001 – December 2007) and in children (study II) September 2006 (June 2000 – October 
2010). The lack of severity of illness scores such as APACHE4 or SOFA5 and comorbidity 
index scores hamper comparison with other studies. 
Moreover, patients were grouped using modified ELSO guidelines (47, 53) which may also 
hinder cohort comparison. Categorisation of patients is inherently problematic but necessary 
to create order and to enable comparison and research. The perfect, utopian grouping with 
unambiguously clear instructions creating fully homogenous groups does not exist. Upon 
inspection, many patients treated at the ECMO Centre Karolinska were categorised in vague 
groups such as “ARDS, other”, “Other respiratory failure” or simply “Other”, and many cases 
were open for subjective interpretation. For example, how should a patient with septic shock 
with an unknown cause be categorised (non-pulmonary infections)? And should a patient 
with pneumothorax, aspiration, and ARDS after falling into the water be classified as 
aspiration pneumonia or ARDS post-op/trauma? We suggested a grouping based on the main 
aetiology of respiratory failure, except in neonates, where the cause for ECMO treatment is 
more often based on a clear diagnosis, e.g. congenital diaphragmatic hernia or meconium 
aspiration syndrome.  
The national causes of death registry is valuable to researchers and provides two pieces of 
vital information: whether the patient is alive and which causes of death were reported. The 
latter is based on a form that must be sent by the physician in charge within three weeks after 
the patient’s death. In the vast majority of cases, this report is not based on autopsy reports 
but rather on the physicians best-informed guess after clinical examination. In 2012, only 
11% of deaths were subject to an autopsy in Sweden (88). For patients who die at home, a 
general practitioner is in charge of reporting the cause of death, if natural causes are expected 
(i.e., no forensic autopsy is deemed required). When extracting the data, it was unclear to us 
who diagnosed the cause of death and by what means. 
7.2.2 Study III and IV 
When designing the follow-up investigations, little was known about long-term life after 
ECMO, and the ECMO Centre Karolinska approved to finance 35-40 patients. Hence, the 
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cohort size was not based on statistical power calculations, and the design was retrospective, 
descriptive and without a matched control group. In a way, the studies, therefore, fall 
somewhere in between a case series and a cohort study. 
Selection bias is a noteworthy limitation in study III and IV. Indeed, only 62% of eligible 
long-term survivors (42% of eligible patients) were investigated. It is possible that the 
patients who died after discharge, rejected participation or did not respond to our mails and 
phone calls were indeed the patients who were struggling the most with cognitive, pulmonary 
or quality of life sequelae. The present findings should be interpreted with this in mind.  
The inclusion of H1N1 patients was widely discussed (see the supplemental digital content 1 
of study III), as was the exclusion of patients who stood out, either because of the reason for 
ECMO treatment (e.g. a patient treated <24 hours as a re-warming procedure after a 
drowning accident) or due to co-morbidities (e.g. a patient with a congenital mental and 
physical handicap who could only participate in the radiographic examinations). We also 
discussed how much the language barrier for non-native speakers would affect the self-report 
forms and cognitive tests. When applying for ethical approval, we sought to exclude patients 
who did not have “at least seven years of European or North American education”. This cut-
off was very rough, and the ethical committee asked us to remove this geographical limitation 
before approving the application. We, therefore, decided to investigate all consecutive 
survivors and to report the results to the individual patients but to exclude some patients’ 
findings from the final articles.  
There are several limitations when comparing patients with median SpO2 <93% to 
“normoxaemic” patients (i.e. ≥93%). First, SpO2 was registered in the patient charts hourly, 
meaning they could represent transient high (or low) values and important events may have 
been missed. Second, the definition allowed a patient who was severely hypoxaemic for the 
first 36 hours followed by a normoxaemic four-day period and then decannulated, to be 
classified as normoxaemic. An alternative would be to define hypoxaemia as a certain 
number of hours with a low saturation, which was done as a post-hoc analysis. Third, the 
hypoxaemia limit was possibly too high, since most clinicians are comfortable having a SpO2 
of 90-92% (~PaO2 8-9 kPa) for days but are far less prone to allow an SpO2 of e.g. 80%. 
Four, the groups (hypoxaemic vs non-hypoxaemic) were not matched, meaning there could 
be unevenly distributed confounders. We tested an alternative definition post-hoc and could 
have redefined hypoxaemia further, but the more statistical tests performed, the higher the 
risk of having a type 1 error. In conclusion, we may have found no statistical reason to reject 
the null hypothesis, but the methodology of this can be questioned for several reasons as per 
the discussion above.  
When interpreting the self-reported findings in study IV, namely quality of life, PTSD, 
anxiety, and depression, one must bear in mind that they may both reflect an actual 
improvement over the years and an adaptation by patients to the situation over time. 
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7.3 CLINICAL IMPLICATIONS 
 
 Survival after ECMO treatment should if possible be presented as survival to 
decannulation and survival to 90 days. If survival to discharge is used, this should be 
clearly defined. 
 
 Although the high mortality in the first months after decannulation is probably often 
expected, a high level of vigilance should reside with clinicians and caretakers 
responsible for ECMO treated patients.  
 
 There is a high risk of cerebral lesions in ECMO treated patients, and silent lesions 
are probably common. Efforts should be made to monitor patients’ cerebral functions, 
especially in the setting of VA ECMO, and a routine for cerebral imaging during and 
after ECMO treatment should be considered. 
 
 Permissive hypoxaemia with an SaO2 as low as 70% may be safe if tissue hypoxia is 
avoided, but there is a paucity of data in this area. 
 
 Long-term sequelae, including cognitive functions, quality of life and pulmonary 
functions, may take years to improve, and some dysfunction seems irreversible. 
Follow-up clinics should be considered for all age groups to early identify treatable 
problems. Patient information based on this knowledge is vital to avoid unnecessary 
suffering and misunderstanding. 
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7.4 FUTURE RESEARCH 
 
 To aid future patient selection, patient and treatment-specific factors which influence 
90-day survival (short-term) and 5-year survival in the group that survives to 90 days 
(long-term) should be further investigated.   
 
 It would be interesting to investigate ECMO patients’ long-term health status in a 
longitudinal fashion, e.g. 1, 3 and 5 years after discharge, since there seems to be a 
large recovery potential in the first years after treatment.  
 
 The damaging effects of hypoxaemia without hypoxia and whether it may cause 
cognitive dysfunction and increased mortality should be further studied. These studies 
should include measurements of oxygen delivery to the brain to account for regional 
flow characteristics and autoregulation.  
 
 The occurrence of brain lesions during and after ECMO should be further investigated 
using a screening protocol rather than a radiography-when-symptoms-occur-
approach. These studies should include investigations after discharge, since silent 
lesions are probably common, and preferably compare to conventionally treated 
matched patients. 
 
 Whether lung parenchymal damage is caused by VILI and may serve as an early 
predictor for long-term dysfunction is worthy of further studies. Furthermore, it is 
currently unknown whether even lower pressures and tidal volumes than 
recommended by the ARDSnet (“ultra-protective ventilation”) could reduce VILI 
further. 
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7.5 REFLECTIONS CONCERNING LEARNING OUTCOMES 
During the five years it took to complete this doctoral thesis, learning has come from a 
multitude of sources. Academic courses have laid the groundwork for scientific thinking and 
understanding, and the process of working on a project from methodological planning to 
revising manuscripts with help from reviewers, supervisors, and co-authors has been 
invaluable. Study I and II constituted good introductions to research thinking, with relatively 
few methodological challenges. Still, they required careful ethical considerations in a time 
when IT system security and patient integrity were lively debated. The process of working on 
the first manuscript took much time and effort, and the initial submission was turned down by 
two journals before eventually being accepted for publication by a third journal after two 
major revisions. This process was in retrospect highly valuable, as it helped me to consider 
study limitations, alternative explanations for our results and how the presentation of the 
findings could be improved. Study II, conceived with the same methods and with similar 
results as study I, was accepted after one round of minor revision, probably reflecting the 
steep learning curve from study I. This process was repeated with study III and IV, where 
study III took many revisions before being accepted, while study IV, when writing this 
summary chapter, has been accepted without revision by a peer-reviewed journal.  
In 2017, I joined the Critical Care Research Group in Brisbane Australia as an international 
research fellow for a year, focusing on projects outside this dissertation while simultaneously 
working on study 3. I cannot overstress the value of spending time in an environment with 
fellow PhD students from other universities and cultures, discussing current and future 
projects and research in general on a daily basis. During my time in Australia, among other 
things, I got acquainted with planning and conduction of large animal and ex-vivo laboratory 
studies, statistical calculations using R statistics, writing literature reviews, supervising 
students and organising a medical conference.  
Another great source of learning has come from the numerous academic meetings where I’ve 
been fortunate to be given the opportunity to present my research, either as abstract posters or 
invited faculty. In my experience, when preparing to present your research in such an 
environment, you reflect about it on a deeper level, trying to anticipate what weaknesses may 
be brought up and how to meet both valid and less relevant criticism.  
All-in-all, as a medical doctor spending most of my time with patients, the above and the 
invaluable help from my supervisors has helped me to grow as a scientist, not necessarily 
always on a very detailed level but as a generalist with a broad understanding of basic 
research concepts, which I’m sure will aid me both clinically and academically in the future. 
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8 CONCLUSION 
Life after ECMO can take many forms, and each patient’s destiny is affected by numerous 
factors.  
Long-term survival after treatment with ECMO was generally good in patients who 
 Survived the first critical months after decannulation 
 Were treated for a fully reversible condition 
 Did not have a severe comorbidity 
After treatment with ECMO for respiratory failure in adults, the present results suggest that 
 Cerebrovascular lesions are common, especially if venoarterial ECMO is used 
 Long-term cognitive functions may be good if the patient has not suffered from a 
cerebrovascular lesion.  
 Patients treated with a permissive hypoxemia approach may have normal long-term 
cognitive functions, but this needs to be further studied. 
 Reduced quality of life, depression, anxiety, and pulmonary dysfunction are common 
many years after treatment, but in line with conventionally treated patients.  
Given the severity of illness and risk of death when admitted for ECMO, these results are 
promising but need further evaluation. It is my hope that this thesis may inspire further 
research on the topic and help health care professionals when discussing life after ECMO 
with patients and relatives. 
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9 SUMMARY OF THESIS IN SWEDISH 
ECMO betyder Extracorporeal (utanför kroppen) MembranOxygenering (syresättning genom 
ett membran) och är en slags hjärt-lung-maskin som används inom intensivvården vid 
allvarlig hjärt- eller lungsjukdom. ECMO botar inte sjukdomen som orsakar problemet, men 
kan hålla patienten vid liv de dagar till veckor (ibland månader) som behövs för att kroppen 
ska återhämta sig. Vanlig intensivvård och behandling av sjukdomen ges parallellt. Vid t.ex. 
allvarlig lunginflammation är första behandlingen att ge extra syrgas och mekanisk 
ventilation. När 100% syrgaskoncentration och höga tryck i respiratorn inte räcker kan 
ECMO vara ett alternativ. Med ECMO sugs det icke syresatta blodet ut från kroppen, leds 
genom membranlungan som syresätter blodet som sedan pumpas tillbaka till kroppen igen. 
Eftersom att ECMO är ett stort avsteg från den vanliga fysiologin, och både är kostsamt och 
behäftat med flera biverkningar, är det viktigt att veta hur det går för dessa patienter senare i 
livet. Detta har undersökts i fyra studier som ligger till grund för den här 
doktorsavhandlingen. 
I studie I och II undersöktes långtidsöverlevnaden för nyfödda, äldre barn och vuxna som 
behandlats med ECMO. Det visade sig att många dör de första tre månaderna efter 
behandling, men att de som överlevt denna kritiska tid ofta har en god överlevnad på sikt, 
förutsatt att de inte har någon allvarlig grundsjukdom som påverkar deras överlevnad (t.ex. 
cancer eller medfödda lungsjukdomar) och att den sjukdom som de behandlats för är 
reversibel (går över, t.ex. en infektion som behandlas lyckosamt med antibiotika). 
I studie III och IV undersöktes 38 vuxna överlevare som vårdats för lungsvikt, i genomsnitt 9 
år efter ECMO-behandling, med magnetkameraundersökning av hjärnan och IQ-tester av en 
psykolog (studie III). Det visade sig att dessa patienter hade en IQ-nivå liknande 
normalbefolkningens, men att tecken till tidigare stroke (antingen från ECMO-tiden eller från 
innan eller efter) var vanligt och att de patienter som haft stroke hade signifikant sämre 
minnes- och exekutiva funktioner. Samma patienter undersöktes även med 
självskattningsformulär för livskvalité, ångest, depression och posttraumatisk stress, samt 
skiktröntgenundersökning av lungorna och lungfunktionsundersökningar. Patienterna hade 
sämre livskvalité och oftare psykologiska besvär än en frisk normalbefolkning, men 
resultaten var på en nivå som motsvarar andra patienter som haft svår lungsvikt och vårdats 
med respirator men utan ECMO. Dock är det svårt att jämföra våra 38 patienter med andra 
studerade grupper, då de kan skilja sig på flera viktiga punkter, och det är också diskutabelt 
om dessa 38 överlevare representerar ECMO-behandlade i stort.  
Sammanfattningsvis tycks ECMO-överlevare som i övrigt är friska ha en god 
långtidsöverlevnad om de överlever den första kritiska tiden efter ECMO-behandlingen. 
Dessa patienter kan ha flertalet problem senare i livet, med sänkt livskvalité och påverkad 
lungfunktion. Det är därför viktigt att dessa patienter följs upp av vården på ett strukturerat 
sätt. Det är också viktigt att övervaka hjärnans funktioner under ECMO-vård, och forska mer 
kring vad man kan göra för att förhindra stroke, eftersom att det kan ge kognitiva besvär 
senare i livet. 
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